Mineralys Therapeutics Statistics
Total Valuation
MLYS has a market cap or net worth of $2.07 billion. The enterprise value is $1.50 billion.
| Market Cap | 2.07B |
| Enterprise Value | 1.50B |
Important Dates
The next estimated earnings date is Monday, November 9, 2026, after market close.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MLYS has 88.41 million shares outstanding. The number of shares has increased by 46.24% in one year.
| Current Share Class | 88.41M |
| Shares Outstanding | 88.41M |
| Shares Change (YoY) | +46.24% |
| Shares Change (QoQ) | +2.28% |
| Owned by Insiders (%) | 0.51% |
| Owned by Institutions (%) | 90.94% |
| Float | 66.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 122.53 |
| PB Ratio | 3.75 |
| P/TBV Ratio | 3.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 34.46, with a Debt / Equity ratio of 0.18.
| Current Ratio | 34.46 |
| Quick Ratio | 34.24 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -80.88% and return on invested capital (ROIC) is -48.18%.
| Return on Equity (ROE) | -80.88% |
| Return on Assets (ROA) | -46.18% |
| Return on Invested Capital (ROIC) | -48.18% |
| Return on Capital Employed (ROCE) | -57.17% |
| Weighted Average Cost of Capital (WACC) | 7.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.60M |
| Employee Count | 76 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.66% in the last 52 weeks. The beta is 0.69, so MLYS's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -37.66% |
| 50-Day Moving Average | 26.45 |
| 200-Day Moving Average | 28.07 |
| Relative Strength Index (RSI) | 39.34 |
| Average Volume (20 Days) | 1,440,950 |
Short Selling Information
The latest short interest is 9.18 million, so 10.39% of the outstanding shares have been sold short.
| Short Interest | 9.18M |
| Short Previous Month | 9.33M |
| Short % of Shares Out | 10.39% |
| Short % of Float | 13.79% |
| Short Ratio (days to cover) | 8.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -370.79M |
| Pretax Income | -349.58M |
| Net Income | -349.58M |
| EBITDA | -370.75M |
| EBIT | -370.79M |
| Earnings Per Share (EPS) | -$4.38 |
Balance Sheet
The company has $661.41 million in cash and $97.62 million in debt, with a net cash position of $563.80 million or $6.38 per share.
| Cash & Cash Equivalents | 661.41M |
| Total Debt | 97.62M |
| Net Cash | 563.80M |
| Net Cash Per Share | $6.38 |
| Equity (Book Value) | 550.92M |
| Book Value Per Share | 6.24 |
| Working Capital | 646.48M |
Cash Flow
In the last 12 months, operating cash flow was -$138.79 million and capital expenditures -$15,000, giving a free cash flow of -$138.80 million.
| Operating Cash Flow | -138.79M |
| Capital Expenditures | -15,000 |
| Depreciation & Amortization | 39,000 |
| Net Borrowing | 97.50M |
| Free Cash Flow | -138.80M |
| FCF Per Share | -$1.57 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MLYS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -46.24% |
| Shareholder Yield | -46.24% |
| Earnings Yield | -16.92% |
| FCF Yield | -6.72% |
Analyst Forecast
The average price target for MLYS is $48.50, which is 107.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $48.50 |
| Price Target Difference | 107.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |